Acridine ester fully automated chemiluminescence immunoassay reagent
Research and testing services
R&D laboratory
Research and Development Achievements
About Us
Company Profile
Beijing North BioNBItechnology Institute Co., Ltd. (hereinafter referred to as “NBI” or the “Company”) was established in 1985 with the approval of the Ministry of Nuclear Industry, as a pioneer in the industrialization of in vitro immunoassay reagents in China. Formerly a subsidiary of China Isotope & Radiation Corporation under China National Nuclear Corporation (CNNC), the Company was acquired by CNNC Healthcare Investment Co., Ltd. in December 2023 to become its wholly-owned subsidiary, marking a new stage of development. By the end of 2025, its total assets reached 935 million yuan, total liabilities 581 million yuan, and total owners’equity 354 million yuan. At present, the Company has 390 active employees and 68 retirees.
As one of China’s earliest institutions engaged in the R&D, production, sales and testing services of immunoassay reagents, over the past four decades, the Company has stayed true to its original aspiration of “providing high-quality products and services for human health” and fulfilled its core mission of “Focusing on In Vitro Diagnostics, Serving Human Health”. With deep roots in the immunoassay sector, it has accumulated profound technical expertise and strong industrialization capabilities. The Company holds nearly 300 product registration certificates. Its production workshops strictly comply with China’s Good Manufacturing Practice (GMP) for pharmaceuticals and the ISO 13485 international quality standard, enabling large-scale production across multiple technical platforms including radioimmunoassay, chemiluminescence immunoassay, enzyme-linked immunosorbent assay and colloidal gold, with a supply capacity of more than 360 diagnostic reagents. Its business network covers all 31 provincial-level regions in China and extends to nearly 30 countries and regions across Southeast Asia, Africa, the Middle East and Europe. It has established a complete sales network for detection products covering oncology, cardiovascular diseases, infectious diseases, respiratory diseases and drugs of abuse, with 134 CE-certified products. To form an industrial closed loop, the Company has proactively completed upstream and downstream industrial layout, establishing three third-party independent medical laboratories in Chengdu, Wuhan and Hefei, and building a modern R&D and production base as well as a marketing platform for diagnostic reagents in Shanghai.
Entering a new development phase, NBI closely aligns with the national "Healthy China" initiative and fully implements the "One-Two-Three" development strategy of CNNC Healthcare. Anchored on its new strategic positioning of “Full Spectrum of Tumor Diagnostics, A Key Force in Nuclear Drug R&D”, the Company will continue to consolidate its leading position in domestic radioimmunoassay. Leveraging the strengths of CNNC and its "Five Certificates and Two Production Lines" qualifications, it will build a domestic substitution R&D platform for tumor diagnostics and establish a full-spectrum product ecosystem. Adhering to both independent R&D and open cooperation, the Company will deploy its BFR series nuclear drug R&D pipeline under the IPD (Integrated Product Development) model to open a second curve of industrial growth. It is committed to building an integrated platform for precision diagnosis and treatment covering the full cycle of tumor “screening–diagnosis–treatment–monitoring”, and accelerating the listing process of its dual main businesses of “diagnostics + nuclear drugs”.
Looking ahead, NBI aspires to be “a leader in tumor diagnosis and treatment, an explorer in the popularization of nuclear drugs”. Grounded in the "Chinese cancer spectrum", guided by a "closed-loop diagnosis and treatment" system, and driven by its "full-chain advantages", the Company will systematically build a full-cycle tumor management system featuring "precision diagnostic testing and targeted therapeutic intervention", and forge a more efficient and accessible new future for tumor diagnosis and treatment.
1985
year
The company was established in
300
+
Product Registration Certificate
300
+
Multiple in vitro diagnostic reagent products
5
family
Covering medical testing, diagnostic reagents, and commercial applications
Subsidiaries engaged in innovative circulation and other businesses
Corporate Culture
Corporate Purpose
Provide high-quality products and services for human health
Corporate Mission
Focusing on in vitro diagnostics to serve human health
Quality Culture
Cultivate quality genes, pursue technological progress, and achieve customer expectations with high-quality products
Development Goals
Focusing on the in vitro diagnostic industry, with scientific research and medical testing as the two wings, striving to build
To become a well-known comprehensive service provider in the in vitro diagnostic industry in China.
Development History
Follow Us
Friendship link:
Copyright @ 2024: Beijing North Biotechnology Research Institute Co., Ltd Beijing ICP No. 05068269-1
Technical Support: Xunxiang Technology
